These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22179855)

  • 1. Cooperation between Polycomb and androgen receptor during oncogenic transformation.
    Zhao JC; Yu J; Runkle C; Wu L; Hu M; Wu D; Liu JS; Wang Q; Qin ZS; Yu J
    Genome Res; 2012 Feb; 22(2):322-31. PubMed ID: 22179855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
    Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
    PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
    Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
    Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
    Kim J; Lee Y; Lu X; Song B; Fong KW; Cao Q; Licht JD; Zhao JC; Yu J
    Cell Rep; 2018 Dec; 25(10):2808-2820.e4. PubMed ID: 30517868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor.
    Wu L; Runkle C; Jin HJ; Yu J; Li J; Yang X; Kuzel T; Lee C; Yu J
    Oncogene; 2014 Jan; 33(4):504-13. PubMed ID: 23318417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer.
    Liu Q; Wang G; Li Q; Jiang W; Kim JS; Wang R; Zhu S; Wang X; Yan L; Yi Y; Zhang L; Meng Q; Li C; Zhao D; Qiao Y; Li Y; Gursel DB; Chinnaiyan AM; Chen K; Cao Q
    Int J Cancer; 2019 Jul; 145(2):415-426. PubMed ID: 30628724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation.
    Wang J; Park KS; Yu X; Gong W; Earp HS; Wang GG; Jin J; Cai L
    Nucleic Acids Res; 2022 Oct; 50(19):10929-10946. PubMed ID: 36300627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.
    Bohrer LR; Chen S; Hallstrom TC; Huang H
    Endocrinology; 2010 Nov; 151(11):5136-45. PubMed ID: 20881251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer.
    Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Urano T; Takahashi S; Homma Y; Aburatani H; Inoue S
    Oncotarget; 2015 Feb; 6(4):2263-76. PubMed ID: 25537508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
    Yu J; Yu J; Mani RS; Cao Q; Brenner CJ; Cao X; Wang X; Wu L; Li J; Hu M; Gong Y; Cheng H; Laxman B; Vellaichamy A; Shankar S; Li Y; Dhanasekaran SM; Morey R; Barrette T; Lonigro RJ; Tomlins SA; Varambally S; Qin ZS; Chinnaiyan AM
    Cancer Cell; 2010 May; 17(5):443-54. PubMed ID: 20478527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
    Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
    Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.
    Xu K; Wu ZJ; Groner AC; He HH; Cai C; Lis RT; Wu X; Stack EC; Loda M; Liu T; Xu H; Cato L; Thornton JE; Gregory RI; Morrissey C; Vessella RL; Montironi R; Magi-Galluzzi C; Kantoff PW; Balk SP; Liu XS; Brown M
    Science; 2012 Dec; 338(6113):1465-9. PubMed ID: 23239736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PVT1 signals an androgen-dependent transcriptional repression program in prostate cancer cells and a set of the repressed genes predicts high-risk tumors.
    Videira A; Beckedorff FC; daSilva LF; Verjovski-Almeida S
    Cell Commun Signal; 2021 Jan; 19(1):5. PubMed ID: 33430890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
    Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
    Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
    Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
    Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCOR-coupled H2A monoubiquitination represses a subset of androgen receptor target genes regulating prostate cancer proliferation.
    Lempiäinen JK; Manjur ABMK; Malinen M; Ketola K; Niskanen EA; Palvimo JJ
    Oncogene; 2020 Mar; 39(11):2391-2407. PubMed ID: 31925334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.
    Chen T; Wang LH; Farrar WL
    Cancer Res; 2000 Apr; 60(8):2132-5. PubMed ID: 10786674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
    Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
    Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.